FDA NEWS
FDA approved label changes for all statins to warn patients of the potential risk of increased blood-glucose levels and diabetes as well as memory loss when taking these medications. » More |
|
FDA has approved 2 separate dosing innovations, including an autoinjector pen, designed to improve the treatment experience for patients receiving once-a-week interferon beta-1a (Avonex, Biogen Idec) for relapsing forms of multiple sclerosis. » More |
CONTINUING EDUCATION
Pharmacists can help with the management of weight loss through nutrition education, exercise counseling, and strategies for medication adherence.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
CLINICAL NEWS
Better access to the opioid antagonist naloxone and better training on how to administer it could help reduce the increasing number of deaths from opioid overdoses, a new report suggests. » More |
|
Intramuscular injections with midazolam may be more effective than the intravenous administrations used by paramedics to stop prolonged seizures, according to a study published February 16 in the New England Journal of Medicine. » More |
|
Researchers said it was “time to sound the alarm” after determining that gonococcus has become less susceptible to the last line of antimicrobial defense over the past 3 years.
» More |
|
The risk of febrile seizure was higher for the first 2 of 3 times that a combination shot containing acellular pertussis vaccine was administered to infants, although the absolute risk remained low, according to a Danish study that appeared in the February 22/29 issue of JAMA. » More |
LONG-TERM CARE
The American Health Care Association and the National Center for Assisted Living launched a multi-year initiative for long-term care that includes reducing off-label use of antipsychotics and hospital readmissions. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
